Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

Click here to view original web page at Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

One U.K. trial is transforming COVID-19 treatment. Why haven’t others delivered more results?

A World Health Organization–led global trial of treatments for COVID-19 was slow to enroll coronavirus-infected people, like this one in a Spanish intensive care unit, whereas a large trial in the United Kingdom quickly produced results for three treatments. […]

Click here to view original web page at One U.K. trial is transforming COVID-19 treatment. Why haven’t others delivered more results?

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Objectives The coronavirus disease 2019 (COVID-19) pandemic has prompted many initiatives to identify safe and efficacious treatments, yet little is known regarding where early efforts have focused. We aimed to characterise registered clinical trials assessing drugs or plasma treatments […]

Click here to view original web page at Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Coronovirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

A phlebotomist draws blood from a patient participating in a clinical trial for a cancer treatment. With hospitals focused on COVID-19, hundreds of studies are being put on hold. Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for […]

Click here to view original web page at www.npr.org

Open Orphan PLC Q&A: Coronavirus challenge study model (LON:ORPH)

Open Orphan PLC (LON:ORPH ) Chief Executive Officer Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss the world’s first human coronavirus challenge study model. Q1: We’ve just seen that you’ve begun the development of the world’s first commercial human coronavirus challenge study model. What can […]

Click here to view original web page at www.directorstalkinterviews.com

A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol.

Abstract Seasonal influenza has a significant annual global impact. Current influenza vaccines work by inducing strain-specific antibodies against the highly polymorphic surface proteins of the influenza virus and need to be redesigned every year, increasing their cost and limiting availability. There is a demand for a more efficacious vaccine, […]

Click here to view original web page at www.ncbi.nlm.nih.gov

GRDG Sciences Announces Successful Antiviral Testing of Equivir Preparations Underway for Coronavirus Testing

BETHESDA, Md., Feb. 25, 2020 /PRNewswire/ — Global Research & Discovery Group Sciences (“GRDG”), a private research and development organization, recently conducted an additional round of antiviral testing of Equivir confirming efficacy against a broad range of viruses. This newest research reinforces previous laboratory testing conducted at multiple independent […]

Click here to view original web page at finance.yahoo.com